BIRC5 and lip and oral cavity carcinoma: Then, we stimulated PBMCs of oral cancer patients with either or both Survivin-C58 and Survivin-2B80-88 peptides, and the consequent CTLs were examined for the peptide-specificity and cytotoxicity against HLA-A24+ tumor cells.